An Open-Label, Dose Escalation, Phase 1 Study of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies.
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2017
At a glance
- Drugs Ixazomib (Primary)
- Indications Cancer; Head and neck cancer; Non-small cell lung cancer; Prostate cancer; Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors Millennium
- 13 Mar 2017 Results (n=755) of pooled analysis of (C16001,C16002,C16003,C16004,C16005,C16007,C16008,C16010,C16013,TB-MC010034) ten studies assessing pharmacokinetic analysis of Ixazomib published in the Clinical Pharmacokinetics.
- 18 Mar 2015 Results published in the Investigational New Drugs.
- 22 Jun 2012 Actual patient number is 116 according to ClinicalTrials.gov.